Journal of cancer research and clinical oncology
-
J. Cancer Res. Clin. Oncol. · Aug 2020
Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer.
After transurethral resection of a bladder tumor, patients frequently have a recurrence of the disease, thereby requiring adjuvant therapy. ⋯ The RECINT model may be useful for stratifying the risk of recurrence in patients with non-muscle-invasive bladder cancer and may allow for identification of those who may benefit the most from adjuvant BCG immunotherapy.